Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VTK-235
- Development stage
- Preclinical
- Lead developer
- Vitarka Therapeutics
- Modality
- PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
01
Overview
VTK-235 is a preclinical-stage targeted protein degrader being developed by Vitarka Therapeutics for the treatment of RAS-driven solid tumors. The drug is designed to act as a Pan-ErbB degrader, targeting the entire ErbB family of receptor tyrosine kinases, which includes Epidermal Growth Factor Receptor (EGFR/ErbB1), HER2 (ErbB2), HER3 (ErbB3), and HER4 (ErbB4). By utilizing a targeted protein degradation (TPD) approach, VTK-235 aims to eliminate these proteins entirely rather than simply inhibiting their kinase activity, potentially overcoming resistance mechanisms common in ErbB-dependent and RAS-mutant cancers. The program is currently in the discovery and efficacy stages of preclinical development.
02
Targets
ERBB3 (Erb-b2 receptor tyrosine kinase 3)EGFR (Epidermal growth factor receptor)ERBB4 (Erb-b2 receptor tyrosine kinase 4)ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on VTK-235.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VTK-235.